Stockscreener 앱 받기
75.08
0.64%
-0.565
전일 마감가:
$75.65
열려 있는:
$75.12
하루 거래량:
221.18K
Relative Volume:
0.05
시가총액:
$44.25B
수익:
$5.54B
순이익/손실:
$4.18B
주가수익비율:
10.73
EPS:
7
순현금흐름:
$259.90M
1주 성능:
-0.50%
1개월 성능:
+8.37%
6개월 성능:
+12.71%
1년 성능:
-11.83%
1일 변동 폭
$74.64
$75.44
1주일 범위
$74.15
$77.12
52주 변동 폭
$58.93
$95.25
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
EW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
75.03 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
|
ABT
Abbott Laboratories
|
131.56 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.17 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
375.05 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
84.00 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace
FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India
FDA Approves First-Ever TAVR Treatment for Asymptomatic Aortic Stenosis Patients - Stock Titan
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq
Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey
Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks
Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance
Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com
Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com
Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize
Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised - Yahoo Finance
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, T - GuruFocus
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, Target Raised | EW Stock News - GuruFocus
Piper Sandler raises Edwards Lifesciences stock to Overweight - Investing.com
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast By Investing.com - Investing.com UK
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Milestones - GuruFocus
Edwards Lifesciences (EW) Reports Strong Q1 2025 Growth on Cardi - GuruFocus
Edwards Lifesciences Reports Strong Q1 Growth - TipRanks
Edwards posts Street-beating Q1 results, ups 2025 sales guidance - MassDevice
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp Q1 2025 Earnings: EPS of $0.62 Beats E - GuruFocus
Edwards Lifesciences raises 2025 sales forecast after robust quarter - marketscreener.com
Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance - marketscreener.com
Innovative Strategy Boosts Edwards Lifesciences (EW) Q1 Revenue Above Expectations | EW Stock News - GuruFocus
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat - MSN
Edwards Lifesciences Reports First Quarter Results - TradingView
Edwards Lifesciences Corp. Reveals Climb In Q1 Profit - Nasdaq
Earnings Flash (EW) Edwards Lifesciences Reports Q1 Adjusted EPS $0.64, vs. FactSet Est of $0.60 - marketscreener.com
Edwards Lifesciences Crushes Q1 Expectations: TMTT Sales Surge 58%, New SAPIEN M3 Approval Fuels Growth - Stock Titan
EDWARDS LIFESCIENCES Earnings Preview: Recent $EW Insider Trading, Hedge Fund Activity, and More - Nasdaq
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue - BioSpace
Lobbying Update: $350,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Nasdaq
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support?Edwards Lifesciences (NYSE:EW) - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com
Q1 2025 Earnings Alert: Edwards Lifesciences Unveils Critical Financial Report Date - Stock Titan
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.73%
자본화:
|
볼륨(24시간):